Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Matthew Sochat (NPI 1518304849)

Field	Value
Entity Type	Individual
Organization	Matthew Sochat
Address	203 Cox Blvd
City	Goldsboro
State	NC
ZIP	27534
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 28, 2013

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider is effectively an outpatient hematology/oncology infusion practice: the top revenue drivers are antineoplastic and biologic injectable drugs (J3245, J9271, J9299) alongside chemotherapy administration and infusion-related CPTs such as 96413 and 96365. The mix of high-volume drug codes and chemotherapy administration/infusion codes indicates the operation centers on in-office infusions and biologic therapy, with supporting lab work (85025, 80053) and E/M visits for ongoing management.

Revenue concentration is heavily skewed toward three injectable drug codes: J3245 (19.2%), J9271 (17.4%), and J9299 (17.3%), which together account for 54.0% of this provider's total Medicare revenue. This degree of concentration around high-cost injectables means changes in utilization, pricing, or payer coverage for those agents would materially affect the provider’s Medicare revenue stream.

The provider’s payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $2M while Medicaid shows none on file, so Medicaid is not a material source of billed volume or revenue for this NPI. Analysts should treat this profile as Medicare-dependent when modeling reimbursement risk or market exposure.

Competitive standing on key oncology drugs is mixed: J3245 ranks #126 of 225 nationally (41th percentile; typical, unremarkable volume), J9271 ranks #1427 of 1841 (23th percentile; typical, unremarkable volume), and J9299 ranks #273 of 505 (46th percentile; typical, unremarkable volume). Those percentile placements indicate the provider is not a national leader on these specific agents but maintains routine, programmatic use consistent with an active infusion practice.

Several codes show above-typical national volume for supportive and bone-health therapies: J0897 (16.8% of Medicare revenue) ranks at the 96th percentile and J1437 (8.6% of Medicare revenue) ranks at the 94th percentile, both described as notably above typical national volume. This suggests a comparatively strong local supply of bone-modifying agents and IV iron, aligning with an oncology practice that also delivers substantial supportive care.

High-intensity E/M and procedure volumes further characterize the practice: 99214 and 99213 rank in the 96th percentile and 99215 in the 98th percentile, indicating notably above-typical outpatient visit volumes for established patients. Those elevated E/M rankings imply ongoing longitudinal management of complex patients rather than infrequent consults.

There are clear statistical outliers in infusion and injection procedure volume: 96372 is at the 99th percentile and labeled an extreme outlier, and 96360 is also at the 99th percentile and labeled an extreme outlier; additional high-percentile procedure codes include 36415 and 85025 at the 98th percentile. These extreme/high outlier procedure volumes point to very high throughput for injections, IV starts, and basic lab monitoring relative to national peers, reinforcing the characterization of a busy infusion clinic.

The provider has an established public presence in Medicare billing, with NPI enumeration on 2013-05-28 (~13 years ago), indicating roughly a decade-plus of billing history. That tenure, combined with concentrated Medicare revenue ($2M) and no Medicaid activity, frames this entity as a stable, Medicare-focused oncology/heme practice whose business risk and market footprint should be evaluated primarily through its Medicare infusion and supportive-care patterns.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

63 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3245	Injection, tildrakizumab, 1 mg	3,400	$110	$370.6K
J9271	Injection, pembrolizumab, 1 mg	7,810	$40	$335.9K
J9299	Injection, nivolumab, 1 mg	13,900	$20	$333.6K
J0897	Injection, denosumab, 1 mg	18,010	$20	$324.1K
J1437	Injection, ferric derisomaltose, 10 mg	9,700	$20	$164.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	780	$90	$71.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	400	$130	$52.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	460	$100	$44.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	650	$60	$40.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	15,600	$1	$31.2K

Showing 1–10 of 63

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Matthew Sochat — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

63 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3245	4	10	3,400	$110	$640.2K
J9271	18	30	9,600	$40	$528.3K
J9299	4	10	10,800	$20	$295.8K
J1437	4	30	2,700	$20	$71.6K
J0897	6	430	2,100	$20	$63.9K
J3490	6	80	50	$450	$24.1K
J0881	3	20	2,370	$1	$22.3K
80053	31	1,400	100	$10	$16.5K
96413	26	280	90	$90	$15.8K
99214	575	18,060	110	$80	$15.1K

Showing 1–10 of 63

Related Providers

Other providers that share a Tax Identification Number (TIN) with Matthew Sochat, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nagesh Jayaram	NC	Hematology & Oncology Physician	$1.8M	$0
Samer Kasbari	NC	Hematology & Oncology Physician	$1.4M	$0
Jason Boyd	NC	Hematology & Oncology Physician	$1.2M	$0
Shonda Asaad	NC	Hematology & Oncology Physician	$707.3K	$0

Nearby Providers

Other providers in the same ZIP code as Matthew Sochat, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Goldsboro Pediatrics PA	NC	Pediatrics Physician	$0	$61.3M
Wayne Memorial Hospital Inc	NC	General Acute Care Hospital	$0	$37.8M
Waynesboro Family Clinic	NC	Mental Health Counselor	$0	$32.8M
Crossroads Support Services, Inc	NC	Home Health Agency	$0	$13.5M
Simmons Early Intervention Therapy, LLC	NC	Developmental Therapist	$0	$12.9M
Howell Support Services	NC	Community/Behavioral Health Agency	$0	$11.5M
Clientfirst Of Nc, LLC	NC	Community/Behavioral Health Agency	$0	$10M
Personal Homecare Solutions, Inc.	NC	Personal Care Attendant	$0	$9.5M
Omni Family Of Services North Carolina Inc.	NC	Community/Behavioral Health Agency	$0	$8.5M
Goldsboro Emergency Medical Specialists, Inc.	NC	Emergency Medicine Physician	$0	$8.2M

Matthew Sochat — Billing Profile & Reimbursement Data

Sign up for Matthew Sochat — Billing Profile & Reimbursement Data policy alerts

Matthew Sochat — Billing Profile & Reimbursement Data

Sign up for Matthew Sochat — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References